Search

Your search keyword '"P. Simone"' showing total 1,406 results

Search Constraints

Start Over You searched for: Author "P. Simone" Remove constraint Author: "P. Simone" Journal blood Remove constraint Journal: blood
1,406 results on '"P. Simone"'

Search Results

1. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

2. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

3. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

4. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank

6. Tumor necrosis factor α promotes clonal dominance of KITD816V+cells in mastocytosis: role of survivin and impact on prognosis

7. GPIbα–filamin A interaction regulates megakaryocyte localization and budding during platelet biogenesis

8. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children

9. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden

10. Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD

11. Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD

13. Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

14. Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

15. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease

16. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease

17. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

18. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

19. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

20. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

23. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

24. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

27. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

28. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

29. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

30. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis

31. Neutrophil HIF-1α stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle

32. Neutrophil HIF-1α stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle

33. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

34. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

35. Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

36. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

37. The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

38. How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

39. Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

40. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53Mutation

41. Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

42. Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

44. HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party

45. Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)

46. Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

47. Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

48. Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study

49. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

50. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Catalog

Books, media, physical & digital resources